The Miyamoto Lab focuses on the discovery and development of novel biomarkers to guide the personalized treatment of patients with prostate and bladder cancer. We focus on two general classes of biomarkers, namely those based on the molecular profiles of tumor biopsies, and those based on circulating tumors cells (CTCs) in the blood that can be sampled non-invasively and repeatedly. By analyzing these patient-derived specimens, we have identified new molecular predictors of response to therapy and potential mechanisms of treatment resistance. Our overall aim is to develop tools for “real-time precision medicine” to probe the molecular signatures of cancers as they evolve over time, and to guide the precise and rational selection of appropriate therapies for each individual patient with prostate or bladder cancer.
Do you want to...
Meet current lab members?
Contact the Principal Investigator?
Support our research?
We welcome three new Miyamoto Lab members: Keisuke who joined us in July 2019, and Erika and Jake who joined us in August 2019. We are glad to have you on our team!
In the podcast Advances at Mass General Cancer Center, Dr. Miyamoto discusses our recent paper in Cancer Discovery on using a digital RNA analysis of CTCs to predict treatment outcomes in metastatic prostate cancer and early dissemination in localized prostate cancer.
The Aid for Cancer Research awarded a grant to Dr. Henning Willers and Dr. David Miyamoto to support their research proposal on investigating mechanisms of DNA repair after proton radiation.
Dr. David Miyamoto was named the Mass General Cancer Center Everyday Amazing Healthcare Professional of the game for the New England Patriots! Click here to listen to Dr. Miyamoto’s radio spot.